Henry Schein (NASDAQ:HSIC) Price Target Lowered to $80.00 at JPMorgan Chase & Co.

Henry Schein (NASDAQ:HSIC) had its price target lowered by stock analysts at JPMorgan Chase & Co. from $88.00 to $80.00 in a report released on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 15.21% from the company’s current price.

A number of other brokerages also recently commented on HSIC. Baird R W raised Henry Schein from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 22nd. Robert W. Baird dropped their price objective on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. UBS Group cut their price objective on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Barrington Research decreased their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $86.00 price target on shares of Henry Schein in a research report on Friday, June 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $77.10.

Henry Schein Price Performance

NASDAQ:HSIC opened at $69.44 on Monday. Henry Schein has a 12-month low of $60.01 and a 12-month high of $82.63. The firm has a market cap of $8.89 billion, a price-to-earnings ratio of 23.46, a price-to-earnings-growth ratio of 1.80 and a beta of 0.87. The company’s 50-day moving average is $67.69 and its two-hundred day moving average is $71.46. The company has a current ratio of 1.75, a quick ratio of 1.02 and a debt-to-equity ratio of 0.47.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.01. The business had revenue of $3.10 billion for the quarter, compared to the consensus estimate of $3.27 billion. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.31 earnings per share. Research analysts expect that Henry Schein will post 5.16 EPS for the current year.

Hedge Funds Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently bought and sold shares of HSIC. Vanguard Group Inc. raised its stake in shares of Henry Schein by 1.7% during the first quarter. Vanguard Group Inc. now owns 15,432,001 shares of the company’s stock valued at $1,165,425,000 after purchasing an additional 260,537 shares during the period. American Century Companies Inc. grew its holdings in Henry Schein by 3.1% during the 2nd quarter. American Century Companies Inc. now owns 5,484,286 shares of the company’s stock valued at $351,543,000 after purchasing an additional 162,477 shares in the last quarter. Swedbank AB purchased a new stake in Henry Schein during the 1st quarter worth $215,998,000. Boston Partners lifted its holdings in Henry Schein by 144.1% in the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock worth $199,393,000 after buying an additional 1,556,831 shares in the last quarter. Finally, Fiduciary Management Inc. WI lifted its holdings in Henry Schein by 17.1% in the 4th quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock worth $172,947,000 after buying an additional 333,855 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.